Eternity in Medical Information -- Medisurf
Search | Web Directory, News, Variable useful Information, PubMed In Medine, All
Category Select :
Items 1 ~ 20 of 3434, Page 1 of 173
1. Merck Foundation Launches Five-Year Initiative to Reduce Disparities in HIV Care for Vulnerable and Underserved Southeastern US Communities
09/04/2019 MERCK
2. WHO revises recommendations on hormonal contraceptive use for women at high HIV risk
08/29/2019 WHO
3. Half of US Teens Getting HPV Vaccinations
The US Centers for Disease Control and Prevention (CDC) reports that just over half (51.1%) of teenagers were fully vaccinated for human papillomavirus (HPV) as of 2018, up 2.5 percentage points from 48.6% in 2017.
08/29/2019 American Cancer Society
4. As Ebola cases reach 3000 in DRC, WHO calls on all partners to fulfill promises to communities
08/29/2019 WHO
5. Rising to the challenge of malaria eradication
08/23/2019 WHO
6. World Bank and WHO Statement on Partnership & Deployment of Financing to WHO for Ebola Response in DRC
08/22/2019 WHO
7. Three years without a case of wild polio virus, Government of Nigeria warns against complacency
08/21/2019 WHO
8. Burundi launches ebola vaccination campaign for health and front-line workers
08/14/2019 WHO
9. Merck Receives Positive EU CHMP Opinion for ZERBAXA® 3g Dose (ceftolozane and tazobactam) for the Treatment of Adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP)
07/29/2019 MERCK
10. Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019
New Findings from Study Evaluating Islatravir in Combination with Doravirine versus DELSTRIGO™ (doravirine 100 mg/3TC 300 mg/tenofovir disoproxil fumarate 300 mg) / Company Plans to Initiate Phase 3 Trials
07/24/2019 MERCK
11. WHO applauds Rwanda’s Ebola preparedness efforts
07/24/2019 WHO
12. Merck Presents Early Evidence on Extended Delivery of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) via Subdermal Implant
Phase 1 Data Presented Today at IAS 2019
07/23/2019 MERCK
13. WHO recommends dolutegravir as preferred HIV treatment option in all populations
07/22/2019 WHO
14. Ebola outbreak in the Democratic Republic of the Congo declared a Public Health Emergency of International Concern
07/17/2019 WHO
15. FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available
07/17/2019 MERCK
16. 20 million children miss out on lifesaving measles, diphtheria and tetanus vaccines in 2018
07/15/2019 WHO
17. High-level meeting on the Ebola outbreak in the Democratic Republic of the Congo affirms support for Government-led response and UN system-wide approach
07/15/2019 WHO
18. Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019
Data Include Week 48 Results from Phase 2B Study Evaluating MK-8591 in Combination with Doravirine
07/10/2019 MERCK
19. WHO updates global guidance on medicines and diagnostic tests to address health challenges, prioritize highly effective therapeutics, and improve affordable access
New essential medicines and diagnostics lists published today
07/09/2019 WHO
20. More than a million people to be vaccinated in phase 2 of a huge cholera vaccination campaign in the Democratic Republic of the Congo
07/03/2019 WHO
   
1 2 3 4 5 6 7 8 9 10
 
경기도 성남시 분당구 구미동 25-1 엘레강스 프라자 ㈜ 메디서프 | Tel : 031-896-0930 | 사업자 등록번호 : 212-81-47247
통신판매신호번호 : 경기 성남 2007-712 | 대표이사 한상욱